Free Trial

Xenon Pharmaceuticals (XENE) Stock Forecast & Price Target

Xenon Pharmaceuticals logo
$42.45 +0.77 (+1.85%)
(As of 11/26/2024 ET)

Xenon Pharmaceuticals - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Sell
0
Hold
0
Buy
12

Based on 12 Wall Street analysts who have issued ratings for Xenon Pharmaceuticals in the last 12 months, the stock has a consensus rating of "Buy." Out of the 12 analysts, 11 have given a buy rating, and 1 has given a strong buy rating for XENE.

Consensus Price Target

$57.45
35.35% Upside
According to the 12 analysts' twelve-month price targets for Xenon Pharmaceuticals, the average price target is $57.45. The highest price target for XENE is $65.00, while the lowest price target for XENE is $49.00. The average price target represents a forecasted upside of 35.35% from the current price of $42.45.
Get the Latest News and Ratings for XENE and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Xenon Pharmaceuticals and its competitors.

Sign Up

XENE Analyst Ratings Over Time

TypeCurrent Forecast
11/27/23 to 11/26/24
1 Month Ago
10/28/23 to 10/27/24
3 Months Ago
8/29/23 to 8/28/24
1 Year Ago
11/27/22 to 11/27/23
Strong Buy
1 Strong Buy rating(s)
1 Strong Buy rating(s)
0 Strong Buy rating(s)
1 Strong Buy rating(s)
Buy
11 Buy rating(s)
11 Buy rating(s)
9 Buy rating(s)
8 Buy rating(s)
Hold
0 Hold rating(s)
0 Hold rating(s)
0 Hold rating(s)
0 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$57.45$57.45$58.78$52.75
Forecasted Upside35.35% Upside37.68% Upside46.65% Upside54.60% Upside
Consensus Rating
Buy
Buy
Buy
Buy

XENE Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

XENE Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Xenon Pharmaceuticals Stock vs. The Competition

TypeXenon PharmaceuticalsMedical CompaniesS&P 500
Consensus Rating Score
3.08
2.80
2.50
Consensus RatingBuyModerate BuyModerate Buy
Predicted Upside35.35% Upside25,264.12% Upside6.71% Upside
News Sentiment Rating
Neutral News

See Recent XENE News
Positive News
Positive News
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
11/13/2024HC Wainwright
2 of 5 stars
D. Tsao
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$53.00 ➝ $53.00+24.82%
11/13/2024Needham & Company LLC
3 of 5 stars
 Reiterated RatingBuy ➝ Buy$60.00 ➝ $60.00+38.28%
10/10/2024Raymond James
4 of 5 stars
D. Brill
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform$50.00+26.84%
9/3/2024Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingOutperform ➝ Outperform$55.00 ➝ $55.00+34.44%
8/30/2024William Blair
Subscribe to MarketBeat All Access for the recommendation accuracy rating
M. Minter
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
8/9/2024Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingOverweight ➝ Overweight$65.00 ➝ $65.00+58.34%
8/9/2024Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOutperform ➝ Outperform$50.00 ➝ $49.00+19.63%
5/10/2024Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetBuy ➝ Buy$62.00 ➝ $60.00+48.00%
1/2/2024Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$52.00 ➝ $56.00+23.67%
12/19/2023JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOutperform$54.00 ➝ $59.00+39.38%
12/18/2023Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$53.00 ➝ $62.00+48.72%
12/8/2023Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageOutperform$63.00+61.37%
12/14/2022The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageBuy$60.00+57.60%
12/12/2022Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageOutperform
11/28/2022Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageOverweight$50.00+43.64%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Tuesday at 11:28 PM ET.


XENE Forecast - Frequently Asked Questions

According to the research reports of 12 Wall Street equities research analysts, the average twelve-month stock price forecast for Xenon Pharmaceuticals is $57.45, with a high forecast of $65.00 and a low forecast of $49.00.

12 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Xenon Pharmaceuticals in the last year. There are currently 11 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" XENE shares.

According to analysts, Xenon Pharmaceuticals's stock has a predicted upside of 35.35% based on their 12-month stock forecasts.

Over the previous 90 days, Xenon Pharmaceuticals's stock had 1 upgrade by analysts.

Xenon Pharmaceuticals has been rated by research analysts at HC Wainwright, Needham & Company LLC, Raymond James, Royal Bank of Canada, and William Blair in the past 90 days.

Analysts like Xenon Pharmaceuticals more than other "medical" companies. The consensus rating for Xenon Pharmaceuticals is Buy while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how XENE compares to other companies.


This page (NASDAQ:XENE) was last updated on 11/26/2024 by MarketBeat.com Staff
From Our Partners